Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC
Status:
WITHDRAWN
Trial end date:
2040-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment